Are innovative payment models required to give patients access to potential disease-modifying therapies for Alzheimer’s disease?
Several potentially disease-modifying therapies (DMT) for Alzheimer’s disease (AD) are currently in final stages of clinical development. If successful, difficult questions will need to be answered regarding how DMT will be used and reimbursed. Such challenges are not unique to the field of AD; however, the scale of the issue would be unparalleled due to the high prevalence, enormous unmet medical need and challenges in determining the value of treatment and aligning the incentives of the multiple stakeholders involved. This symposium will provide a critical assessment of the applicability of innovative payment models to AD DMT, and develop proposals for which models can be considered under different circumstances.
Admission: Free, pre-registration required to gunilla.johansson@ki.se (number of participants limited)
- Read the program (pdf) Updated October 28